Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | WDR5 | P61964 | 5/20 | 0.37 |
| ▸ | GAA | P10253 | 3/20 | 0.36 |
| ▸ | CCR2 | P41597 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29217890 | 0.81 | KIF11 (0.42) | WDR5CCR2 | |
| SCHEMBL2593145 | 0.81 | WDR5 (0.40) | SMN1; SMN2TSHRGLAWDR5GAA | |
| SCHEMBL16019385 | 0.79 | SMN1; SMN2 (0.55) | SMN1; SMN2GLAALDH1A1LMNA | |
| SCHEMBL16019358 | 0.78 | KDM4E (0.37) | SMN1; SMN2TSHRCCR2HTT | |
| SCHEMBL16019362 | 0.78 | CCR2 (0.41) | TSHRCCR2ALDH1A1 | |
| SCHEMBL23291833 | 0.77 | WDR5 (0.35) | SMN1; SMN2TSHRGLAWDR5GAA | |
| SCHEMBL23291772 | 0.77 | PTGDR2 (0.38) | TSHRWDR5PTGDR2ALDH1A1CYP2D6 | |
| SCHEMBL16019408 | 0.77 | SMN1; SMN2 (0.32) | SMN1; SMN2 | |
| SCHEMBL3112984 | 0.76 | CCR2 (0.44) | SMN1; SMN2TSHRGLAWDR5GAA | |
| SCHEMBL4157506 | 0.74 | LMNA (0.47) | SMN1; SMN2TSHRGLAWDR5CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9693556-B2 | Herbicidal pyridazinone derivatives | SYNGENTA LIMITED (GB) | 2017-07-04 | — | — | US | disclosed |
| US-9693556-B2 | Herbicidal pyridazinone derivatives | SYNGENTA LIMITED (GB) | 2017-07-04 | — | — | US | disclosed |
| US-20140256546-A1 | HERBICIDAL PYRIDAZINONE DERIVATIVES | SYNGENTA LIMITED (GB) | 2014-09-11 | — | — | US | disclosed |
| US-20140256546-A1 | HERBICIDAL PYRIDAZINONE DERIVATIVES | SYNGENTA LIMITED (GB) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256546-A1 | HERBICIDAL PYRIDAZINONE DERIVATIVES | PRDX6, PRDX1, CBR3 | SMN1; SMN2 4594/4885TSHR 391/4885GLA 3844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.